Literature DB >> 16627976

Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cells.

Ajay Goel1, Florentine Fuerst, Erin Hotchkiss, C Richard Boland.   

Abstract

While there is an increasing interest in selenium chemoprevention against human colon polyp recurrence and other cancers, the mechanism(s) by which these agents inhibit carcinogenesis are uncertain. Some of the proposed mechanisms include the inhibition of cytosine methyltransferases, carcinogen bioactivation, and inhibition of cyclooxygenase (COX). More recently, it has been suggested that selenium may exert growth inhibitory effects by activating p53. However, the molecular mechanisms of action of selenomethionine, an organoselenium compound present in selenized yeast and currently being investigated in human clinical trials for colon polyp prevention, are unclear. In the present study we tested the hypothesis that selenomethionine might affect colon cancer cell growth by p53 mediated apoptosis and/or cell cycle regulation. Four human colon cancer cell lines including HCT116 and RKO (wild type p53), HCT116-p53KO (isogenic control of HCT116 cells with p53 knocked out) and Caco-2 (mutant p53) were treated with 0-100 microM of selenomethionine for 24, 48 and 72 h. Cell viability rates were determined by the MTT assay. Cell cycle analysis was performed by flow cytometry and apoptosis measured by Annexin V-Cy5 staining. Expression of p53 protein was determined by Western blotting and immunofluorescence assays. All cell lines showed concentration and time dependent growth inhibition with selenomethionine, although HCT116 and RKO cells were the most sensitive to such treatments. Interestingly, although HCT116 and HCT116-p53KO are isogenic cell lines, selenomethionine caused a G2/M cell cycle arrest in HCT116 and RKO cells, but not in HCT116-p53KO cells. Similarly, both HCT116 and RKO demonstrated a significant increase in apoptosis (100-170%; p < 0.01) with 50-100 microM selenomethionine. Cell cycle arrest and apoptosis observed in HCT116 and RKO cell lines were accompanied by a marked increase in p53 protein expression following selenium treatment. These results clearly suggest that selenomethionine exerts p53 dependent growth inhibitory effects in colon cancer cells by inducing G2/M cell cycle arrest as well as apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627976     DOI: 10.4161/cbt.5.5.2654

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  19 in total

1.  Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells.

Authors:  Rui Zhao; Nong Xiang; Fredrick E Domann; Weixiong Zhong
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

2.  Expression of NHERF1 in colonic tumors induced by 1,2-dimethylhydrazine in rats is independent of plasma ovarian steroids.

Authors:  Mariana Troncoso; F Darío Cuello Carrión; Elina Guiñazu; Mariel A Fanelli; Magdalena Montt-Guevara; Rómulo L Cabrini; Rubén W Carón; Erica L Kreimann
Journal:  Horm Cancer       Date:  2011-08       Impact factor: 3.869

3.  Protective effects of selenocystine against γ-radiation-induced genotoxicity in Swiss albino mice.

Authors:  Amit Kunwar; S Jayakumar; H N Bhilwade; P P Bag; H Bhatt; R C Chaubey; K I Priyadarsini
Journal:  Radiat Environ Biophys       Date:  2011-01-23       Impact factor: 1.925

4.  Selenium compounds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells.

Authors:  Yongmei Qi; Norberta W Schoene; Frederick M Lartey; Wen-Hsing Cheng
Journal:  J Biol Chem       Date:  2010-08-06       Impact factor: 5.157

5.  Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation.

Authors:  Meijun Long; Juekun Wu; Junwen Hao; Wei Liu; Yong Tang; Xi Li; Hang Su; Wanshou Qiu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-07-21       Impact factor: 2.416

6.  Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells.

Authors:  Aye Aye Thant; Yanyuan Wu; Jane Lee; Dhruva Kumar Mishra; Heather Garcia; H Phillip Koeffler; Jaydutt V Vadgama
Journal:  Anticancer Res       Date:  2008 Nov-Dec       Impact factor: 2.480

Review 7.  Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.

Authors:  Junxuan Lü; Jinhui Zhang; Cheng Jiang; Yibin Deng; Nur Özten; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2015-11-23       Impact factor: 2.900

8.  Selenium and risk of bladder cancer: a population-based case-control study.

Authors:  Kristin Wallace; Karl T Kelsey; Alan Schned; J Steven Morris; Angeline S Andrew; Margaret R Karagas
Journal:  Cancer Prev Res (Phila)       Date:  2009-01

9.  Subchronic oral toxicity studies of Se-methylselenocysteine, an organoselenium compound for breast cancer prevention.

Authors:  W D Johnson; R L Morrissey; I Kapetanovic; J A Crowell; D L McCormick
Journal:  Food Chem Toxicol       Date:  2007-11-12       Impact factor: 6.023

10.  Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells.

Authors:  Hui Nian; William H Bisson; Wan-Mohaiza Dashwood; John T Pinto; Roderick H Dashwood
Journal:  Carcinogenesis       Date:  2009-06-15       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.